ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Update

ABVC BioPharma, Inc. (NASDAQ:ABVCGet Free Report) was the target of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 435,100 shares, a decline of 26.0% from the May 15th total of 587,600 shares. Approximately 4.9% of the shares of the company are sold short. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is presently 0.4 days.

ABVC BioPharma Stock Up 3.5 %

Shares of NASDAQ:ABVC opened at $0.86 on Friday. ABVC BioPharma has a 52-week low of $0.67 and a 52-week high of $6.87. The stock has a market cap of $9.32 million, a price-to-earnings ratio of -0.38 and a beta of 0.71. The business has a 50-day moving average price of $1.05 and a 200-day moving average price of $1.20.

ABVC BioPharma (NASDAQ:ABVCGet Free Report) last posted its quarterly earnings results on Friday, May 17th. The company reported ($0.40) earnings per share (EPS) for the quarter. ABVC BioPharma had a negative return on equity of 207.72% and a negative net margin of 50,504.00%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ABVC BioPharma stock. Chase Investment Counsel Corp acquired a new stake in ABVC BioPharma, Inc. (NASDAQ:ABVCFree Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 178,377 shares of the company’s stock, valued at approximately $233,000. Chase Investment Counsel Corp owned 1.69% of ABVC BioPharma as of its most recent SEC filing. Institutional investors and hedge funds own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

(Get Free Report)

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.

Read More

Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.